Dr. Feliciano on Nivolumab in Small Cell Lung Cancer

Josephine L. Feliciano, MD
Published: Monday, Aug 27, 2018



Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).

In August, the FDA granted an accelerated approval of single-agent nivolumab for the treatment of patients with SCLC with disease progression after platinum-based chemotherapy and 1 other line of therapy. This gives patients another therapeutic option, says Feliciano, though patients with progressive SCLC tend to experience a lot of physical decline, so selecting the right patients will be important.

The approval of nivolumab was based on the results of the CheckMate-032 trial in which patients with extensive-stage SCLC were randomized to nivolumab and nivolumab plus ipilimumab (Yervoy). Data indicated an objective response rate of approximately 12% (95% CI, 6.5-19.5) with single-agent nivolumab and some durable responses, notes Feliciano.

Eleven percent of patients experienced a partial response and 0.9% experienced a complete response. The median duration of response was 17.9 months (95% CI, 7.9-42.1). At 12 months, 62% patients continued to show a response to the therapy, with 39% of patients still responding at 18 months.


Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).

In August, the FDA granted an accelerated approval of single-agent nivolumab for the treatment of patients with SCLC with disease progression after platinum-based chemotherapy and 1 other line of therapy. This gives patients another therapeutic option, says Feliciano, though patients with progressive SCLC tend to experience a lot of physical decline, so selecting the right patients will be important.

The approval of nivolumab was based on the results of the CheckMate-032 trial in which patients with extensive-stage SCLC were randomized to nivolumab and nivolumab plus ipilimumab (Yervoy). Data indicated an objective response rate of approximately 12% (95% CI, 6.5-19.5) with single-agent nivolumab and some durable responses, notes Feliciano.

Eleven percent of patients experienced a partial response and 0.9% experienced a complete response. The median duration of response was 17.9 months (95% CI, 7.9-42.1). At 12 months, 62% patients continued to show a response to the therapy, with 39% of patients still responding at 18 months.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x